Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline to prevent recurrence of diabetic foot ulcer
ChiCTR2100048510Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pentoxifylline in diabetic foot ulcer (DFU) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Recurrence rate of diabetic foot ulcer. Started Mar 2021; status: recruiting.
02
Drugs
pentoxifylline
03
Conditions
diabetic foot ulcer (DFU)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100048510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048510.